Lexicon Pharmaceuticals (LXRX) Competitors $0.50 -0.01 (-2.36%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LXRX vs. ZBIO, RIGL, VSTM, EBS, VNDA, XOMA, IRWD, CDXS, SGMO, and RGLSShould you be buying Lexicon Pharmaceuticals stock or one of its competitors? The main competitors of Lexicon Pharmaceuticals include Zenas Biopharma (ZBIO), Rigel Pharmaceuticals (RIGL), Verastem (VSTM), Emergent BioSolutions (EBS), Vanda Pharmaceuticals (VNDA), XOMA (XOMA), Ironwood Pharmaceuticals (IRWD), Codexis (CDXS), Sangamo Therapeutics (SGMO), and Regulus Therapeutics (RGLS). These companies are all part of the "biotechnology" industry. Lexicon Pharmaceuticals vs. Zenas Biopharma Rigel Pharmaceuticals Verastem Emergent BioSolutions Vanda Pharmaceuticals XOMA Ironwood Pharmaceuticals Codexis Sangamo Therapeutics Regulus Therapeutics Lexicon Pharmaceuticals (NASDAQ:LXRX) and Zenas Biopharma (NASDAQ:ZBIO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, community ranking, institutional ownership, dividends, profitability and earnings. Which has stronger valuation & earnings, LXRX or ZBIO? Zenas Biopharma has lower revenue, but higher earnings than Lexicon Pharmaceuticals. Zenas Biopharma is trading at a lower price-to-earnings ratio than Lexicon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLexicon Pharmaceuticals$31.08M3.96-$177.12M-$0.64-0.78Zenas Biopharma$5M69.64-$148.39M-$3.55-2.35 Do analysts prefer LXRX or ZBIO? Lexicon Pharmaceuticals currently has a consensus target price of $3.67, suggesting a potential upside of 633.33%. Zenas Biopharma has a consensus target price of $40.00, suggesting a potential upside of 380.19%. Given Lexicon Pharmaceuticals' higher possible upside, equities analysts clearly believe Lexicon Pharmaceuticals is more favorable than Zenas Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lexicon Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40Zenas Biopharma 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor LXRX or ZBIO? In the previous week, Zenas Biopharma had 11 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 12 mentions for Zenas Biopharma and 1 mentions for Lexicon Pharmaceuticals. Lexicon Pharmaceuticals' average media sentiment score of 0.82 beat Zenas Biopharma's score of 0.05 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lexicon Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zenas Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 11 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Is LXRX or ZBIO more profitable? Zenas Biopharma has a net margin of 0.00% compared to Lexicon Pharmaceuticals' net margin of -4,109.41%. Zenas Biopharma's return on equity of 0.00% beat Lexicon Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Lexicon Pharmaceuticals-4,109.41% -107.38% -64.09% Zenas Biopharma N/A N/A N/A Does the MarketBeat Community favor LXRX or ZBIO? Lexicon Pharmaceuticals received 482 more outperform votes than Zenas Biopharma when rated by MarketBeat users. However, 100.00% of users gave Zenas Biopharma an outperform vote while only 64.11% of users gave Lexicon Pharmaceuticals an outperform vote. CompanyUnderperformOutperformLexicon PharmaceuticalsOutperform Votes48464.11% Underperform Votes27135.89% Zenas BiopharmaOutperform Votes2100.00% Underperform VotesNo Votes Do institutionals & insiders have more ownership in LXRX or ZBIO? 74.7% of Lexicon Pharmaceuticals shares are held by institutional investors. 4.5% of Lexicon Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. SummaryLexicon Pharmaceuticals and Zenas Biopharma tied by winning 8 of the 16 factors compared between the two stocks. Remove Ads Get Lexicon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for LXRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LXRX vs. The Competition Export to ExcelMetricLexicon PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$123.12M$6.26B$5.29B$7.35BDividend YieldN/A3.24%5.11%4.32%P/E Ratio-0.676.6921.6517.68Price / Sales3.96222.70371.0992.89Price / CashN/A65.6738.1534.64Price / Book1.325.776.373.94Net Income-$177.12M$142.01M$3.20B$247.45M7 Day Performance1.85%2.88%1.79%0.48%1 Month Performance36.43%-13.93%-9.41%-7.08%1 Year Performance-70.50%-12.36%9.61%-0.35% Lexicon Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LXRXLexicon Pharmaceuticals2.8166 of 5 stars$0.50-2.4%$3.67+633.3%-72.6%$123.12M$31.08M-0.67140Analyst ForecastZBIOZenas BiopharmaN/A$7.89+2.3%$40.00+407.0%N/A$329.79M$5M-2.22N/ANews CoverageGap DownRIGLRigel Pharmaceuticals2.7678 of 5 stars$16.66-3.4%$36.80+120.9%+48.2%$302.55M$179.28M120.99160News CoveragePositive NewsVSTMVerastem3.0735 of 5 stars$4.98-3.5%$13.88+178.6%-56.5%$258.16M$10M-1.5750EBSEmergent BioSolutions4.3126 of 5 stars$4.39-3.0%$14.33+226.9%+134.1%$241.85M$1.01B-1.092,420Positive NewsVNDAVanda Pharmaceuticals4.1686 of 5 stars$4.16+0.4%$16.50+297.1%+7.6%$241.72M$198.77M-12.95290News CoveragePositive NewsXOMAXOMA4.3661 of 5 stars$19.69+1.3%$72.00+265.6%-14.5%$238.55M$10.22M-5.7210Gap UpIRWDIronwood Pharmaceuticals4.5629 of 5 stars$1.21-10.1%$8.60+613.7%-90.7%$194.43M$351.41M-40.50220Analyst DowngradeShort Interest ↓Analyst RevisionNews CoverageGap DownCDXSCodexis3.1454 of 5 stars$2.05-4.0%$8.33+307.5%-16.4%$171.89M$59.35M-2.39250Gap DownSGMOSangamo Therapeutics2.2007 of 5 stars$0.66-0.2%$5.17+688.8%+33.0%$148.31M$57.80M-0.88480Gap DownRGLSRegulus Therapeutics2.424 of 5 stars$1.64-3.0%$12.75+679.8%-29.9%$110.56MN/A-1.5630Short Interest ↑Gap Down Remove Ads Related Companies and Tools Related Companies ZBIO Alternatives RIGL Alternatives VSTM Alternatives EBS Alternatives VNDA Alternatives XOMA Alternatives IRWD Alternatives CDXS Alternatives SGMO Alternatives RGLS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LXRX) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredMarkets in Chaos? Here’s What to Do.Wall Street's on edge with tariffs. And volatility? It's not slowing down. You've seen the headlines… Bu...Investors Alley | SponsoredCatastrophicThe losses are catastrophic... $760 billion wiped off the Magnificent 7, in a single day.InvestorPlace | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredCould this be my downfall?I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredRead before the next tariff announcementLarry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredTrump to unlock 15-figure fortune for America (May 3rd) ?Recently, President Trump decided to kill the coin, for good reason. It now costs 4 cents to make a single pen...Paradigm Press | SponsoredThe real reason gold is soaring (and likely to continue)Trump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexicon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexicon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy LXRX Stock Free LXRX Stock Alerts